Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 4/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923560 | 0.84 | GRM2 (0.55) | HTR2CHTR2AGRM2PSMB1PSMB5 | |
| SCHEMBL20786928 | 0.81 | HDAC3 (0.47) | HTR2CHTR2AGRM2PSMB1PSMB5 | |
| SCHEMBL20808710 | 0.81 | PSMB1 (0.41) | HTR2CHTR2AGRM2PSMB1PSMB5 | |
| SCHEMBL20809182 | 0.81 | PSMB1 (0.41) | HTR2CHTR2AGRM2PSMB1PSMB5 | |
| SCHEMBL1500208 | 0.80 | PSMB1 (0.43) | HTR2CHTR2AGRM2PSMB1PSMB5 | |
| SCHEMBL20786912 | 0.80 | HSD17B10 (0.42) | HTR2CHTR2AGRM2PSMB1PSMB5 | |
| SCHEMBL20786935 | 0.80 | GRM2 (0.41) | HTR2CHTR2AGRM2PSMB1PSMB5 | |
| SCHEMBL5310274 | 0.80 | HTR6 (0.43) | HTR2CHTR2AGRM2HTR1DTDP1 | |
| SCHEMBL20540198 | 0.79 | HTR2C (0.61) | HTR2CHTR2AEGFRHTR1D | |
| SCHEMBL20786954 | 0.79 | PSMB1 (0.41) | HTR2CHTR2AGRM2PSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3453707-B1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3453707-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2019-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | TLR8, TLR1, TLR5 | HTR2C 663/4885HTR2A 692/4885EGFR 608/4885 |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | TLR8, TLR1, TLR5 | HTR2C 663/4885HTR2A 692/4885EGFR 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.